Renal protective effect of YM598, a selective endothelin ET A receptor antagonist, against diabetic nephropathy in OLETF rats

By Sugimoto K.-i.   Tsuruoka S.   Fujimura A.  

European Journal of Pharmacology, Vol. 450, Iss. 2, 2002-08 ,pp. : 183-189

Elsevier

Access to resources Recommend Favorite

Pharmacological profile of YM348, a novel, potent and orally active 5-HT 2C receptor agonist

By Kimura Y.   Hatanaka K.-i.   Naitou Y.   Maeno K.   Shimada I.   Koakutsu A.   Wanibuchi F.   Yamaguchi T.  

European Journal of Pharmacology, Vol. 483, Iss. 1, 2004-01 ,pp. : 37-43

Elsevier

Access to resources Recommend Favorite

Pharmacology of A-216546: a highly selective antagonist for endothelin ET A receptor

By Wu-Wong J.R.   Dixon D.B.   Chiou W.J.   Dayton B.D.   Novosad E.I.   Adler A.L.   Wessale J.L.   Calzadilla S.V.   Hernandez L.   Marsh K.C.   Liu G.   Szczepankiewicz B.   von Geldern T.W.   Opgenorth T.J.  

European Journal of Pharmacology, Vol. 366, Iss. 2, 1999-02 ,pp. : 189-201

Elsevier

Access to resources Recommend Favorite

Pharmacological characterization of YM471, a novel potent vasopressin V 1A and V 2 receptor antagonist

By Tsukada J.   Tahara A.   Tomura Y.   Wada K.-i.   Kusayama T.   Ishii N.   Aoki M.   Yatsu T.   Uchida W.   Taniguchi N.   Tanaka A.  

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 129-138

Elsevier

Access to resources Recommend Favorite

An orally active non-selective endothelin receptor antagonist, bosentan, markedly reduces injury in a rat model of colitis

By Hogaboam C.M.   Muller M.J.   Collins S.M.   Hunt R.H.  

European Journal of Pharmacology, Vol. 309, Iss. 3, 1996-08 ,pp. : 261-269

Elsevier

Access to resources Recommend Favorite